Galectin Therapeutics Inc. - Warrants
GALTW
GALTW was delisted on the 23rd of March, 2017.
5 hedge funds and large institutions have $123K invested in Galectin Therapeutics Inc. - Warrants in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$226K |
| 2 |
Neuberger Berman Group
New York
|
+$44.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.44K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.03K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$47 |
Top Sellers
GALTW Hedge Fund Activity: Q3 2016 in Review
5 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics Inc. - Warrants (GALTW) for Q3 2016, worth a combined $123K.
Buyers outnumbered sellers: 5 funds opened new GALTW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $226K.
- 5 institutional investors held Galectin Therapeutics Inc. - Warrants (GALTW) as of Q3 2016, up from 0 in Q2 2016.
- Funds reported $123K of Galectin Therapeutics Inc. - Warrants stock for Q3 2016.
- 5 funds opened new Galectin Therapeutics Inc. - Warrants positions in Q3 2016 and 0 closed out, a net change of +5 holders.
- The largest Galectin Therapeutics Inc. - Warrants buyer in Q3 2016 was Millennium Management, an estimated $226K added.
Based on aggregated 13F filings for Q3 2016.